Table 1.
Clinical characteristics and major genetic features of the BCP ALL cohorts included in the analysis
| Characteristics | Cohort 1 (SIH, n = 166) | Cohort 2 (LUH, n = 182) | Cohort 3 (JALSG, n = 71) | Cohort 4 (MaSpore, n = 194) | Cohort 5 (TARGET/COG, n = 394) | Cohort 6 (TARGET/COG, n = 216) | Total (n = 1,223) |
| Age at diagnosis | |||||||
| Mean, y | 19.41 | 5.04 | 15.42 | 5.84 | 17.96 | 7.87 | 12.60 |
| Median, y | 15.01 | 4.00 | 17.00 | 4.56 | 13.00 | 6.44 | 7.95 |
| <18 y | 91 (55) | 182 (100) | 39 (55) | 194 (100) | 248 (63) | 152 (70) | 906 (74) |
| ≥18 y | 75 (45) | 0 | 32 (45) | 0 | 145 (37) | 6 (3) | 258 (21) |
| Not available | 0 | 0 | 0 | 0 | 1 | 58 (27) | 59 (5) |
| Gender | |||||||
| Male | 95 (57) | 107 (59) | 30 (42) | 111 (57) | 209 (53) | 105 (49) | 657 (54) |
| Female | 71 (43) | 75 (41) | 41 (58) | 83 (43) | 185 (47) | 111 (51) | 566 (46) |
| Fusions | |||||||
| BCR–ABL1 | 27 (16) | 5 (3) | NA | 9 (5) | 12 (3) | 6 (3) | 59 (5) |
| ETV6–RUNX1 | 19 (11) | 45 (25) | 2 (3) | 36 (19) | 18 (5) | 14 (6) | 134 (11) |
| TCF3–PBX1 | 17 (10) | 13 (7) | 6 (8) | 13 (7) | 11 (3) | 16 (7) | 76 (6) |
| KMT2A | 8 (5) | 14 (8) | 2 (3) | 7 (4) | 9 (2) | 6 (3) | 46 (4) |
| DUX4 | 9 (5) | 8 (4) | 10 (14) | 23 (12) | NA | 2 (1) | 52 (4) |
| MEF2D | 7 (4) | 1 (1) | 7 (10) | 2 (1) | 18 (5) | 5 (2) | 40 (3) |
| ZNF384 | 15 (9) | 2 (1) | 10 (14) | 11 (6) | 11 (3) | 17 (8) | 66 (5) |
Data are years or no. of patients (%). Percentages might not add up to 100% because of rounding. Note: Cohort 3 (JALSG) does not include BCR–ABL patients. NA, not available.